RespireRx Pharmaceuticals (OTCQB:RSPI) will present new information at the 2017 Marcum MicroCap Conference.
As quoted in the press release:
Company’s President, Chief Executive Officer and Vice Chairman of the Board of Directors, Dr. James S. Manuso will discuss results from the successfully completed PACE Phase 2B trial, conducted by Dr. David Carley and colleagues at the University of Illinois at Chicago and Northwestern University, in which dronabinol (oral) was tested for the treatment of obstructive sleep apnea (“OSA”). In addition, Dr. Manuso will discuss results from a successfully completed Phase 2A trial, in which acutely administered CX-1739 (oral) reduced opioid-induced respiratory depression in a clinical model of chronic opioid consumption. Dr. Manuso will also provide a summary of near term plans and goals, background information and descriptions of other product pipeline candidates.
Dr. Manuso’s presentation will be available by live webcast streaming online and archived for 90 days. To access the webcast, go to http://wsw.com/webcast/marcum5/rspi or visit the RespireRx website at www.respirerx.com, click on the same link on the home page, or, click on the Investors tab and follow the links to this press release and click the webcast link.